Cerebrolysin

Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.

• Alzheimer's Disease - Mixed Evidence
• Vascular Dementia - Established Efficacy
• Post-Stroke Cognitive Recovery

Direct brain delivery, standardized dosing, extensive clinical evidence, ready-to-use formulation

IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors

Peak plasma concentration: 30 min. Elimination half-life: 1 hr. Largely cleared by: ~5 hrs.

Research protocols from published literature — not dosing recommendations.

• Piracetam — Compatible: Safe combination demonstrated in clinical studies with no significant interactions. Both compounds work through different mechanisms to support cognitive function.
• Donepezil — Compatible: No significant interactions reported. May have synergistic cognitive effects when used together in Alzheimer's treatment protocols.
• SSRIs — Monitor Combination: Potential additive neurotropic effects. Monitor for enhanced antidepressant effects and consider dose adjustment if combining long-term.
• Tricyclic Antidepressants — Use Caution: May have additive neurological effects. Requires careful monitoring and potential dose adjustments of antidepressant medications.
• Amino Acid Solutions — Avoid Combination: Contraindicated per official prescribing information. Cerebrolysin should not be mixed with balanced amino acid solutions in same infusion.
• Cardiovascular Medications — Avoid Combination: Official prescribing information states Cerebrolysin should not be mixed with cardiovascular medicinal products in same infusion.
• Vitamin Solutions — Avoid Combination: Per official guidelines, Cerebrolysin should not be mixed with vitamin solutions in same IV infusion due to compatibility issues.
• Noopept — Monitor Combination: Both enhance BDNF and affect glutamatergic signaling. Cerebrolysin contains neurotrophic peptides, Noopept modulates AMPA/NMDA receptors. Potential for additive cognitive effects - start with lower doses when combining and monitor for overstimulation.

Supplies:

• Cerebrolysin ampoules (5, 10, or 20 mL)
• Saline, Ringer solution, or 5% glucose (minimum 100 mL for infusion)
• Disposable one-way IV infusion sets and cannulas
• Sterile syringes and alcohol swabs

1. 1Break ampoule and extract Cerebrolysin contents immediately before use
2. 2For direct injection: Up to 10 mL IV undiluted (slow over 3 minutes) or up to 5 mL IM undiluted
3. 3For infusion: Dilute 10-50 mL Cerebrolysin to minimum 100 mL total volume with compatible solution
4. 4Start infusion immediately after dilution - infuse within 15 minutes
5. 5Flush IV catheter with sodium chloride solution before and after administration
6. 6Use disposable one-way infusion sets - discard after use to guarantee sterility

Week 1-2: Initial neuroprotective effects, possible mild side effects (dizziness, agitation). Week 2-4: Neurological improvements become apparent, cognitive function may begin to improve. Week 4-8: Continued recovery, motor function improvements in stroke/TBI patients. Week 8-12: Sustained benefits, cognitive enhancement plateaus in chronic conditions.

Monitor for allergic reactions during first administration - generally well tolerated. Contraindicated in epilepsy and severe renal insufficiency per official prescribing information. Clinical evidence shows mixed results - some large studies positive, others neutral. Research integrity concerns have been raised about some published studies. Not approved in USA but used clinically in over 50 countries worldwide. Use disposable one-way infusion sets to guarantee sterility.

Monitor for allergic reactions during first administration - generally well tolerated. Contraindicated in epilepsy and severe renal insufficiency per official prescribing information. Clinical evidence shows mixed results - some large studies positive, others neutral. Research integrity concerns have been raised about some published studies. Not approved in USA but used clinically in over 50 countries worldwide. Use disposable one-way infusion sets to guarantee sterility.

Cerebrolysin should be stored at Room temperature ≤25°C, protect from light, never freeze.